及早鎖住年輕精緻美！HArmonyCa™美神針™一次即現提升+Boost Up膠原

對抗皮膚鬆弛和失去彈性，真的一分鐘都不可以浪費！HArmonyCa™美神針™的獨特在於以專利技術層遞糅合兩大醫美元素透明質酸及CaHA²，才能帶來即時提升、持效緊緻的協同成效^1*†‡。

科研數據證實，與同類型膠原增生產品相比，從療程後第一週開始就能更高度滲透入肌膚之內^3§，喚活新生膠原⁴，並於第2週起展現更顯著及更持久的拉提力^3§！HArmonyCa™美神針™ 有效重啟膠原再生力量，臨床實證能持效拉提肌膚，長效達12個月，更獲99%用家見證改善效果^5,‖,¶。

不少未曾接觸醫美的女生或會擔心效果不自然，而認為只要局部改善就能避免，卻忽略了應注意全臉平衡感，才能更好地滿足個人需求。不只修飾五官的美態，更要注重作為五官框架、主宰年輕質感的臉部輪廓。

HArmonyCa™美神針™配合獨特「C-Shape拉提」手法，定點支撐出流暢的臉部外輪廓線條^1*†‡，穩住抗初老的第一道防線！以透明質酸成份從肌底支撐出即時豐顏，同時以CaHA成份激活纖維母細胞，促進膠原自生，並逐漸形成緊密細緻的膠原蛋白結構^1*†‡，持效展現緊緻、自然感，無懼皮肉分離，讓大家能在任何年齡階段都展現出更顯年輕活力的自我。

源自於全球醫美領導廠商 Allergan Aesthetics，HArmonyCa™美神針™與另一高端醫美品牌 Juvéderm^®喬雅登^®同屬法國製造。其主要成分與身體相容，亦可被代謝分解⁶，而產品也獲得歐盟CE的認證⁷，放心又可靠！另外，配方中更含有利多卡因減痛配方 ⁸，為療程大大減低不適感。

原來重拾年輕緊緻感，只要選擇合適的醫美療程就真正做得到！你還在猶豫什麼？立即鎖定HArmonyCa™美神針™，用一瞬間將流失的光陰全都追回來～

有關療程細節，請向各大醫學美容中心查詢！立即搜尋原廠供應 : https://bit.ly/3ZLDAs0

^{*Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration and safety profile.1 †Ultrasound and elastography examinations were performed using the Samsung HT 30 ultrasound machine and the ElastoScan HS30/XH30 respectively (Samsung Healthcare Global). When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment an increase in collagen in the treated areas was confirmed.1 ‡Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in FTV at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile-range) increased by 2.2 (1.6– 2.2) mm and 2.0 (1.7–2.2) mm in the right and left side, respectively p<0.0001 each, 180 days after treatment.1 § Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks which showed that HArmonyCa™ led to an instant and sustained lift following injection.3 ‖Results from a 1-year, prospective, open-label, post-marketing study where HArmonyCa™ and HArmonyCa™ Lidocaine were injected in the midface of 140 patients with moderate to severe midface volume deficit. The primary endpoint was responder status based on EI-assessed MFVDS at Month 1. Secondary endpoints included responder status based on EI-assessed and participant-assessed GAIS, change from baseline on FACE-Q Satisfaction with Cheeks questionnaire and change from baseline on FACE-Q Satisfaction with Facial Appearance questionnaire. The mITT population was all treated participants with non-missing baseline MFVDS score. At Month 1, the MFVDS responder status (a participant with at least 1-grade improvement on the MFVDS based on the EI’s live assessment of midface volume deficit) was 82.8% (95% CI: 75.7%–88.5%) in the mITT population for both treatment groups combined.5 ¶The EI-assessed GAIS responder rate (improved or much improved) was 98.5% at Month 1, 98.5% at Month 3, 94.7% at Month 6, 87.8% at Month 9 and 75.6% at Month 12. The participant-assessed GAIS responder rate (improved or much improved) was 91.8% at Month 1, 86.4% at Month 3, 81.2% at Month 6, 75.4% at Month 9 and 72.6% at Month 12.5}

^{References: 1. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;22(8):2186–2197; 2. Allergan Aesthetics. Data on File. HArmonyCa™ Manufacturing. October 2023. REF-98172; 3. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine ABVRRTI77172. Lift capacity. October 2023. REF-84448; 4. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine. Clinical Study Report. July 2022. REF-99624; 5. Allergan Aesthetics. Data on File. M21-787 Responder Rates. REF-125579; 6. Segal T et al. 2014 – Post marketing study of safety and efficacy of Crystalys, a calcium hydroxyapatite based filler for facial soft tissue augmentation. Available at: https://www.kosmetischemedizin-online.de/uebersichtsarbeit/post-marketingstudie-zur-sicherheit-und-wirksamkeit-von-crystalys-einem-auf-calcium-hydroxyapatit-basierenden-filler-fuer-die-weichteilaugmentation-im-gesicht/. Accessed July 2021; 7. European Commission, HArmonyCa Lidocaine. CE certificate number: 145133-21-05-21, May 2021; 8. HArmonyCa™ IFU. 20072591. M049 V02/P01. Revision December 2021.} 

^{HArmonyCa™ (Calcium hydroxyapatite, hyaluronic acid gel with lidocaine). Juvéderm®(Hyaluronic Acid Gel with Lidocaine) 產品系列包括VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA®(HKMD-210451) 及VOLITE™ (HKMD-180040). All adverse events should be reported to MedDeviceComplaintsAPAC@abbvie.com. Suite 2404-08, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong. Tel: (852) 2610 2525 © 2024 Allergan Aesthetics. All rights reserved.} 

^{HK-HAR-240066 | 06/NOV/24; HK-HAR-240067 | 08/NOV/24}